Ground Truth Labs
We decode the bone marrow to improve human health.
Est 2019
Published Jul 15, 2026
The digital pathology AI market is expanding with increasing lab partnerships and clinical workflow integration, but regulatory and data governance remain major gating factors. GTL’s niche focus suggests potentially fewer, deeper deployments compared with broad platform vendors.
| Starting Price | Not publicly listed (quote-based) | Typically not public (enterprise/biopharma contracts) | Public procurement pricing documentation exists |
| Primary focus | Bone marrow morphology quantification and research/trial support | Broad computational pathology platform and biopharma biomarker work | Established AI platform with procurement documentation |
| Key strength | Narrow clinical focus (bone marrow) and university spinout affiliation; emphasis on reproducibility and cohort context | Scale, partnerships, and a broader menu of capabilities | Standardized platform packaging and procurement visibility |
| Key weakness | Limited independent reviews; pricing opacity; unclear regulatory status publicly | Can be enterprise-heavy and may involve platform lock-in concerns | May require more in-house model development or workflow tailoring for some use cases |
—